

ACTIVE CEPI-FUNDED VACCINE CANDIDATE PORTFOLIO BY PHASE

C E P I

	Preclinical	Phase I	Phase II	Phase IIb/III & III	Registration
 Lassa fever		University of Oxford	IAVI		
 MERS	Uvax	IDT	Barinthus/ University of Oxford		
 Nipah		PHV	University of Oxford		
 Rift Valley fever	UC Davis	Afrigen	Wageningen U.	University of Oxford and KEMRI – Wellcome Trust	
 Chikungunya				IVI/Bharat	Valneva
 COVID-19*					SK Bioscience
					Biological E
					Moderna
					Clover
					Novavax
					AZ/Oxford
					University of Hong Kong
 Broadly protective Betacoronavirus	VIDO	Panacea/ THSTI			
	IVI consortium	CPI/CalTech			
	Bharat/U Syd/ExcellGene	Intravacc			
	SK Bioscience				
 Mpox			BioNTech		

(*) CEPI has also funded booster studies of SARS-CoV-2 vaccines developed by Medigen and Vaxxinity

CEPI PORTFOLIO PAGE 1 OF 4 | LAST UPDATED: 8 JAN 2026

ACTIVE CEPI-FUNDED VACCINE CANDIDATE PORTFOLIO BY PHASE

C E P I

	Preclinical	Phase I	Phase II	Phase IIb/III & III	Registration
Disease X	<div style="display: flex; justify-content: space-around;"> <div style="text-align: center;"> <div>Akagera</div> <div>Chungbuk University</div> <div>University of Queensland</div> <div>Moderna</div> <div>SK bio</div> <div>University of Oxford</div> <div>Boost Biopharma</div> <div>Centivax</div> <div>ACM Bio</div> <div>IVI consortium</div> </div> <div style="text-align: center;"> <div>POP BIO</div> <div>Gennova*</div> <div>Emervax</div> <div>HMRI</div> <div>Imperial</div> <div>Nagasaki University</div> <div>VitriVax</div> <div>Abera Bioscience</div> <div>Sinergium</div> </div> </div>				
 Broadly protective Filovirus vaccines	<div style="display: flex; justify-content: space-around;"> <div style="text-align: center;"> <div>Adaptvac</div> <div>Stanford</div> </div> <div style="text-align: center;"> <div>Oxford/ Leipzig/ Moderna</div> </div> </div>				

(*) Gennova funding supports platform optimisation and development of candidate vaccines against Rabies and Nipah virus.

CEPI PORTFOLIO PAGE 2 OF 4 | LAST UPDATED 8 JAN 2026

(‡) Includes Lassa, MERS and Nipah funding

** Funding is part of a total investment of up to \$90m.

Rift Valley fever, Chikungunya, and some COVID-19 and other projects are supported by European Commission co-funding.

DISEASE	DEVELOPER	PHASE	TECHNOLOGY	CEPI FUNDING (IN USD)
 Lassa fever	University of Oxford	Phase I	Viral Vector	Up to \$19 million‡
	IAVI	Phase II	Viral Vector	Up to \$64.4 million
 MERS	University of Oxford + Barinthus	Phase I	Viral vector	Up to \$47 million‡
	IDT	Phase I	Viral vector	Up to \$36 million
 Nipah	Uvax bio	Preclinical	Protein based	Up to \$2.6 million
	University of Oxford	Phase II	Viral Vector	Up to \$19 million‡
 Rift Valley fever	PHV	Phase I	Viral vector	Up to \$43.6 million
	UC Davis	Preclinical	Live attenuated	Up to \$40 million
	Wageningen University	Phase I	Live attenuated	Up to \$38.4 million
	University of Oxford and KEMRI-Wellcome Trust	Phase II	Viral Vector	Up to \$3.7 million
	Afrigen	Preclinical	mRNA	Up to \$6.2 million
	IVI/Bharat	Phase IIb/III	Inactivated virus	Up to \$14.1 million
 Chikungunya	Valneva	Registration	Live attenuated	Up to \$65.9 million
	SK Bioscience	Registration	Protein based	Up to \$210 million
 COVID-19	Biological E	Registration	Protein based	Up to \$14 million
	Moderna	Registration	Protein based	Up to \$1 million
	Clover	Registration	Protein based	Up to \$397.4 million
	University of Hong Kong	Registration	Live attenuated	Up to \$5.4 million
	AZ/University of Oxford	Registration	Viral vector	Up to \$384 million
	Novavax	Registration	Protein based	Up to \$399 million
	BioNTech	Phase I/II	mRNA	Up to \$72 million**
 MpoX				

(##) Includes \$13.38 million for funding a Nipah candidate and \$3.6 million for funding for a Rabies candidate/platform optimisation.

 Broadly protective Betacoronavirus	IVI Consortium	Preclinical	mRNA	Up to \$23.9 million
	VIDO	Preclinical	Protein based	Up to \$22 million
	Bharat/ U Sydney/ ExcellGene	Preclinical	Protein based	Up to \$19.9 million
	CPI/Caltech	Preclinical	Protein based	Up to \$30 million
	SK Bioscience	Preclinical	Protein based	Up to \$50 million
	Panacea/THSTI	Preclinical	Protein based	Up to \$12.5 million
	Intravacc	Preclinical	Protein based	Up to \$4.8 million
 Disease X	Abera Bioscience	Preclinical	Protein based	Up to \$1.5 million
	Akagera	Preclinical	mRNA	Up to \$1.5 million
	ACM Bio	Preclinical	mRNA	Up to \$2.9 million
	Boost Biopharma	Preclinical	Protein based	Up to \$5 million
	Centivax	Preclinical	mRNA	Up to \$5.0 million
	Chungbuk National University	Preclinical	SaRNA	Up to \$0.9 million
	Emervax	Preclinical	CircRNA	Up to \$2.2 million
	Gennova	Preclinical	mRNA	Up to \$16.98 million##
	HMRI	Preclinical	CircRNA	Up to \$3.8 million
	Imperial College London	Preclinical	SaRNA	Up to \$8.4 million
	IVI, KDCA, ST Pharm, Seoul National University	Preclinical	mRNA	Up to \$16 million
	Moderna	Phase II	mRNA	Up to \$54.3 million
	Nagasaki University	Preclinical	mRNA	Up to \$5 million
	University of Oxford	Preclinical	Viral Vector	Up to \$80 million
	POP BIO	Preclinical	Protein based	Up to \$1.5 million
	University of Queensland	Preclinical	Protein based	Up to \$10.6 million
	Sinergium	Preclinical	mRNA	Up to \$1 million
	SK Bioscience	Preclinical	mRNA	Up to \$40 million
	VitriVax	Preclinical	Inactivated virus/Protein based	Up to \$5 million
 Broadly protective Filovirus vaccines	AdaptVac	Preclinical	Virus-like particle	Up to \$12.4 million
	Stanford School of Medicine	Preclinical	Protein nanoparticle	Up to \$18 million
	University of Oxford, Leipzig Institute for Drug Discovery, Moderna	Preclinical	ChAdOx and mRNA	Up to \$26.7 million